New Sedative Prescriptions at Discharge Linked to 20% Higher Fall Risk and Elevated 30-Day Mortality in Adults 66+
Observational cohort data link new post-discharge sedatives to measurable harms in older adults, revealing an unmonitored prescribing practice. Absolute risks are modest but systemically important; randomized deprescribing trials are now required to confirm causality and guide policy.
Hospitals rarely quantify or audit sedative initiation at discharge, leaving community providers without structured deprescribing pathways. Future work must test bundled interventions including mandatory medication review within 14 days and electronic alerts tied to Beers lists. Without such trials, the observed associations will continue to translate into preventable falls, readmissions, and deaths.
Ontario Health: Within 24 months, at least three large academic centers will publish results from randomized trials of discharge sedative deprescribing bundles showing >=15% relative reduction in 30-day falls.
Sources (3)
- [1]Primary Source(https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251965)
- [2]Supporting Source(https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789943)
- [3]Supporting Source(https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(22)00123-4/fulltext)